Marginal zone lymphoma, Waldenström macroglobulinemia/Lymphoplasmacytic lymphoma, multicentric Castleman disease
Conditions
Interventions
Gold Standard:Histopathological evaluation
Index test:PET/CT image analysis of 68Ga NOTA-BCMA nanobody
Sponsors
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18–85 years, with no restriction on sex; 2. Treatment-naïve or relapsed patients with MZL, WM/LPL, or MCD, with histopathological confirmation from at least one lesion; 3. Provision of written informed consent and ability to comply with study follow-up.
Exclusion criteria
Exclusion criteria: 1. Severe hepatic or renal dysfunction; 2. Women who are planning pregnancy, pregnant, or breastfeeding, as well as women who plan to conceive during the study period; participants of childbearing potential are required to use effective contraception throughout the study; 3. Inability to remain in the supine position for at least 30 minutes; 4. Claustrophobia or other psychiatric disorders resulting in poor compliance that would preclude participation in this study; 5. Any other condition deemed by the investigators to render the participant unsuitable for enrollment in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lesion detection rate using the 68Ga-NOTA-BCMA PET/CT tracer;sensitivity;specificity; | — |
Countries
China
Contacts
Public ContactJian Li
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Outcome results
None listed